BioNTech SE (BNTX) has released an update.
Pfizer and BioNTech’s combination mRNA vaccine for influenza and COVID-19 reached a critical milestone in their Phase 3 trial, successfully meeting one of the primary immunogenicity goals for individuals aged 18-64. However, the vaccine fell short on efficacy against the influenza B strain, prompting an evaluation for potential adjustments. Separately, Pfizer’s Phase 2 trial of a second-generation influenza vaccine showed promising results, with plans to further discuss the program with health authorities.
For further insights into BNTX stock, check out TipRanks’ Stock Analysis page.
